))
Catch up on the latest updates on non-small cell lung cancer treatment from the 2024 American Society of Clinical Oncology Annual Meeting, the World Conference on Lung Cancer, and the European Society for Medical Oncology Congress in this exclusive conference coverage series.
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joshua E. Reuss, MD The phase 2 ICARUS-Lung01 study evaluated not only the efficacy and safety of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), but also potential biomarkers associated with response and/or resistance. Here to discuss…
…
continue reading
Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Brain metastases are a frequent complication of lung cancer, which is why the TROPION-Lung05 trial evaluated the intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced metastatic non-small cell lung cancer (NSCLC). According to the data, Dato-DXd demonst…
…
continue reading
